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Abstract: Neuropeptide Y (NPY), colocalized with norepinephrine neuron, is known to modulate 
sympathetic activity and feeding behavior. Although experimental type 1 diabetes has increased 
sympathetic activity at the early part of the disease process, little effort was made so far to 
understand the correlation between NPY level in the hypothalamus and sympathetic activity in 
diabetes. Male Sprague Dawley rats were made diabetic by a single injection of streptozotocin 
(65 mg/kg body weight, IV). The animals were then studied after 2, 4, and 8 weeks. Control animals 
received only citrate vehicle. In an effort to clarify the modulatory effect of NPY at the early stage 
of diabetes, the paraventricular nucleus (PVN) of hypothalamus was sampled by microdialysis 
for NPY and norepinephrine level. While NPY level was increased immediately within 2 weeks 
(along with feeding behavior), norepinephrine level was increased only after 8 weeks following 
injection of streptozotocin. The animals lost significant weight. These results are interpreted to 
mean that a strong correlation exists between the feeding behavior and NPY level in PVN. Since 
NPY is known to inhibit sympathetic activity it is possible that NPY receptors are down-regulated 
following diabetes. The higher level of   norepinephrine indicating higher sympathetic activity 
did not allow the animals to gain weight. In addition, controversy exists regarding pleiotropic 
activities of NPY related to the feeding behavior of these animals.
Keywords: streptozotocin-induced diabetes, increased sympathetic activity, feeding behavior, 
down-regulation of NPY receptors
Introduction
The hypothalamus controls many organs and bodily functions in health and disease, 
including diabetes.1,2 The   paraventricular nucleus (PVN) produces neuropeptide Y 
(NPY) which is colocalized with catecholamines.3,4 NPY is a peptide involved in 
the regulation of body weight, energy balance, and sympathetic tone and its action 
is believed to be mediated through another peptide, leptin.5–7 Leptin is a circulating 
hormone which is produced by adipocytes and its plasma level is increased in obese 
individuals and type 2 diabetes. It has been shown earlier that normally NPY activity 
is suppressed by leptin, and the NPY-leptin axis is involved in the regulation of food 
intake, energy expenditure, and the development of obesity in type 2 diabetes via 
decreased sympathetic activity.5–7
In type 1 diabetes, in which the defect lies in the availability of insulin, the exact 
role of NPY on sympathetic activity is not known. Apparently in experimental type 
1 diabetes the animals failed to gain weight in spite of the fact that the NPY concen-
tration in the hypothalamic regions was increased.8–10 The question therefore arises 
as to whether or not NPY-leptin axis or NPY-sympathetic activity may provide some International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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insight into overall regulation of food intake. Since insulin 
(or leptin) is known to inhibit NPY synthesis and increase 
sympathetic activity,7 PVN appears to be overactive in 
insulin-deficient diabetic rats and could contribute to the 
compensatory hyperphagia and reduced energy expenditure. 
However, such   hypothesis is unlikely to be true due to the 
presence of increased sympathetic activity observed in type 
1 diabetic animals.2,9 As indicated early, the animals fail to 
gain weight although NPY levels are   significantly increased 
in PVN. We therefore, wanted to study the levels of NPY 
and norepinephrine in PVN during the progression of dia-
betes following injection of   streptozotocin which is known 
to produce type 1 diabetes. The aim was to correlate body 
weight and feeding behavior of these animals in relation 
to the levels of NPY and sympathetic activity. We did not 
attempt to evaluate the NPY-leptin axis since sympathetic 
activity has been shown to increase (and not decrease) after 
8 weeks of streptozotocin injection.
Methods
Male Sprague-Dawley rats (175–200 g) of the same age were 
rendered diabetic by a single intrafemoral vein   injection 
of streptozotocin (65 mg/kg body weight) dissolved in a 
  citrate-buffered vehicle (pH 4.5). Age-matched normal rats 
injected with citrate buffer alone were used as controls. 
All rats were provided with food and water ad libitum during 
the entire experiment.
The diabetic animals were subdivided randomly into three 
groups. The first group of diabetic animals was   sacrificed 2, 4 
and 8 weeks after streptozotocin injection; the control animals 
were matched accordingly. The animals in the second group 
were injected with 3 U protamine zinc insulin/day subcutane-
ously for the last 4 weeks before sacrifice at 8 weeks.
Plasma samples were analyzed for blood glucose and 
insulin. The research protocol was approved by the Animal 
Care Committee at the Arabian Gulf University and the 
entire research was carried out according to the guidelines 
for ethical use/handling of small animals.
To collect the extracellular fluid from PVN, microdi-
alysis experiments were carried out as described earlier.11 
The animals were anesthetized by intramuscular injection 
of ketamine xylazine mixture (40 mg ketamine and 4 mg of 
xylazine) and a microdialysis probe was inserted under the 
guidance of a stereotaxic instrument. The microdialysates 
were collected after one hour and then sent to clinical 
chemistry for the levels of NPY and norepinephrine to be 
measured by a high pressure liquid chromatography system 
as described in detail earlier.11,12 The animals were sacrificed 
after the microdialysis experiments.
The results are expressed as mean ± SEM and analyzed 
statistically by factorial analysis of variance. All groups were 
analyzed statistically with post hoc testing using Scheffe’s 
procedure. A P value of less than 0.05 was taken to reflect a 
significant difference between two groups.
Results
Table 1 shows the general characteristic features of the dif-
ferent experimental groups. As expected, following strepto-
zotocin injection, the mean body weight of this group was 
significantly lower after 8 weeks as compared to the control 
group. Severe hyperglycemia in the presence of significantly 
depressed plasma insulin levels was also observed. Food 
consumption on the other hand, was increased in diabetic 
animals. These characteristics are similar to those reported 
earlier.1,2 Daily injection for 2 weeks with 3 U insulin to 
the 4-week diabetic animals partly reversed the observed 
changes (Table 1).
Figures 1 and 2 show the extracellular content of norepi-
nephrine and NPY in PVN of the hypothalamus   measured 
after microdialysis sampling at different stages of diabetes, 
respectively. While NPY level was significantly increased 
following the development of diabetes (Figure 2), norepi-
nephrine concentration did not increase till 8 weeks following 
streptozotocin injection (Figure 1). Norepineprine concen-
tration (nmol/L) was 12.8 ± 1.5 after 8 weeks of diabetes 
as compared to 1.1 ± 0.4 in control animals. Such increase 
was statistically significant (P value was less than 0.05). 
Four weeks of diabetes plus insulin treatment reduced the 
norepinephrine level to 4.6 ± 0.7. The increased level of nor-
epinephrine strengthens the view that increased sympathetic 
Table 1 General characteristics of experimental animals (8 weeks study)
Control (n = 14) Diabetes (n = 16) Diabetes plus insulin 
(n = 10)
Body weight (g)  448 ± 11 275 ± 13* 330 ± 8*
Plasma glucose (mM)  4.5 ± 0.2 15.2 ± 1.1* 5.2 ± 0.6
Plasma insulin (μU/mL)  33 ± 2 13 ± 2* 29 ± 4
Food consumption (g/day)  25 ± 4 48 ± 3*  28 ± 3
Notes: Values are means + se for 40 animals. *P , 0.05.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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activity occurs (including cardiomyopathy) in diabetes after 
8 weeks of study.1,2 On the other hand, the NPY level was 
immediately increased following diabetes (control 12 ± 1; 
two weeks after diabetes, 55 ± 8). The results were also 
statistically significant as the P value was less than 0.05. 
Figure 2 further indicates that eight weeks following diabetes, 
the NPY level continued to increase (72 ± 12). These results 
are unlikely to be artifactual in nature as insulin treatment 
partly reversed the levels (20 ± 3).
Discussion
It has been shown earlier that NPY is involved in the regula-
tion of body weight, energy balance and sympathetic tone. 
Egawa et al13 have shown that central administration of 
NPY affects the sympathetic activity to interscapular brown 
adipose tissue and the suppressive effect of NPY is quite 
predominant. It is therefore generally agreed that NPY is a 
neurochemical modulator of the sympathetic nervous system 
which controls energy expenditure. NPY exerts its major 
feeding effect in PVN of the hypothalamus which receives 
a dense NPY/agouti-related peptide projection from the 
arcuate nucleus. Since insulin (and leptin) inhibits the syn-
thesis of NPY, it is believed that in obesity and noninsulin 
diabetes (type 2 diabetes), the hypothalamus is resistant to 
inhibition by insulin (and leptin) and peptide projection in 
arcuate nucleus-PVN is stimulated leading to a rise in NPY 
level, hyperphagia, sympathetic inhibition, reduced energy 
expenditure, and enhanced weight gain.8
Our results are significant because the animals (type 1 
diabetes) behaved in a completely different way to previous 
studies.14–16 Whereas NPY level was increased immediately, 
the sympathetic activity did not decrease after injection of 
streptozotocin. As a matter of fact sympathetic activity as 
measured by the level of NE in PVN was increased signifi-
cantly at a later stage of diabetes.
We have also reported earlier1,2 that 8-weeks diabetic 
rats had higher sympathetic tone based on NE content, turn-
over, synthesis, and release. Although higher sympathetic 
  activity supports increased energy expenditure and weight 
loss in our model, it failed to resolve the issue as to why the 
sympathetic activity would be increased in the presence of 
higher NPY level. However, based on our previous reports 
it is very likely that NPY receptors are down-regulated 
  following the development of diabetes and it failed to elicit 
inhibition as is often found in hypertension and congestive 
heart failure.12
There is now compelling evidence supporting a role of 
insulin in regulation of the sympathetic nervous system. For 
example, infusion of insulin during euglycemic clamping sig-
nificantly increases plasma catecholamine concentrations and 
regional ‘spillover’.17,18 Such behavior in sympathetic activity 
is likely to happen in type 2 diabetes where the availability or 
production of insulin is usually unaffected. However, the data 
presented here support the view that the central mechanism 
involved in appetite, body weight, and sympathetic regulation 
differs in type 1 (insulin dependent) diabetes. The sympathetic 
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Figure 1 norepinephrine level of paraventricular nucleus (y-axis) in different microdialysates from various groups of diabetic animals. For a detailed description of the exact 
values and statistical significance, please refer to the Results section. Values are means of 10 animals in each group.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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system is increased after a brief period and is directly cor-
related with the NPY level in the hypothalamus, with body 
weight, and feeding behavior. It is certainly interesting to 
know if there is a down-regulation of NPY receptors follow-
ing streptozotocin-induced diabetes mellitus. As indicated 
earlier, we have shown that NPY receptors are down-regulated 
in situations where overproduction of norepinephrine exists 
such as in congestive heart failure.12
In conclusion, we strongly believe that the role of NPY 
in different types of diabetes varies. In the presence of a 
high level of NPY, type 1 (insulin dependent) diabetes is 
associated with increased sympathetic tone, increased energy 
expenditure, and weight loss. Type 2 (insulin independent) 
diabetes on the other hand may mimic obesity due to 
decreased sympathetic tone induced directly by a higher level 
of NPY. The role of leptin should also be considered when 
the hypothalamic regulation of energy balance is evaluated, 
particularly in situations such as type 2 diabetes.
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Figure 2 neuropeptide Y level of paraventricular nucleus (y-axis) in different microdialysates from various groups of diabetic animals. For a detailed description of the exact 
values and statistical significance, please refer to the Results section. Values are means of 10 animals in each group.International Journal of General Medicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-general-medicine-journal
The International Journal of General Medicine is an international, 
peer-reviewed open-access journal that focuses on general and internal 
medicine, pathogenesis, epidemiology, diagnosis, monitoring and treat-
ment protocols. The journal is characterized by the rapid reporting of 
reviews, original research and clinical studies across all disease areas. 
A key focus is the elucidation of disease processes and management 
protocols resulting in improved outcomes for the patient.The manu-
script management system is completely online and includes a very 
quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
325
nPY and diabetes
  13.  Egawa M, Yoshimatsu H, Bray GA. Neuropeptide Y suppresses 
  sympathetic activity to interscapular brown adipose tissue in rats. Am 
J Physiol. 1991;260:R328–R334.
  14.  Ganguly PK, Pierce GN, Dhalla NS. Diabetic cardiomyopathy: 
  membrane dysfunction and therapeutic strategies. J Appl Cardiol. 1987; 
2:323–338.
  15.  Ganguly PK. Neuropeptide receptors: future therapeutic target in 
  congestive heart failure. J Health Sci. 2000;46:430–433.
  16.  Ganguly PK, Rice KM, Panagia V , Dhalla NS. Sarcolemmal phosphati-
dylethanolamine N-methylation in diabetic cardiomyopathy. Circ Res. 
1984;55:504–512.
  17.  Tack CJJ, Lenders JWM, Willemsen JJ, et al. Insulin stimulates epi-
nephrine release under euglycemic conditions in human. Metabolism. 
1998;47:243–249.
  18.  Patel JN, Coppack SW, Goldstein DS, Miles JM, Eisenhofer G. Norepi-
nephrine spillover in forearm and subcutaneous adipose tissue before 
and after eating. J Clin Endocrin Metabol. 2002;87:3373–3377.